- Report
- February 2024
- 150 Pages
Global
From €4323EUR$4,750USD£3,672GBP
- Report
- February 2024
- 70 Pages
South Africa
From €4323EUR$4,750USD£3,672GBP
- Report
- February 2024
- 70 Pages
Indonesia
From €4323EUR$4,750USD£3,672GBP
- Report
- February 2024
- 70 Pages
Philippines
From €4323EUR$4,750USD£3,672GBP
- Report
- February 2024
- 70 Pages
India
From €4323EUR$4,750USD£3,672GBP
- Report
- August 2023
- 75 Pages
North America
From €4323EUR$4,750USD£3,672GBP
- Report
- August 2023
- 150 Pages
North America
From €4323EUR$4,750USD£3,672GBP
- Report
- August 2023
- 70 Pages
Africa, Middle East
From €4323EUR$4,750USD£3,672GBP
- Report
- August 2023
- 70 Pages
South Korea
From €4323EUR$4,750USD£3,672GBP
- Report
- August 2023
- 70 Pages
Latin America
From €4323EUR$4,750USD£3,672GBP
- Report
- October 2022
- 70 Pages
Africa
From €4323EUR$4,750USD£3,672GBP
- Report
- August 2020
- 150 Pages
Global
From €3868EUR$4,250USD£3,285GBP
From €546EUR$600USD£464GBP
- Report
- March 2025
- 50 Pages
Switzerland
From €546EUR$600USD£464GBP
- Report
- March 2025
- 50 Pages
Netherlands
From €546EUR$600USD£464GBP
- Report
- March 2025
- 50 Pages
Malaysia
From €546EUR$600USD£464GBP
- Report
- March 2025
- 50 Pages
Bangladesh
From €546EUR$600USD£464GBP
- Report
- March 2025
- 50 Pages
Philippines
From €546EUR$600USD£464GBP
- Report
- March 2025
- 50 Pages
Thailand
From €546EUR$600USD£464GBP
- Report
- March 2025
- 50 Pages
Singapore
From €546EUR$600USD£464GBP

The Sodium Dependent Glucose Co Transporter 2 (SGLT2) market is a subset of the Endocrine and Metabolic Disorders Drugs market. SGLT2 inhibitors are a class of drugs used to treat type 2 diabetes, a chronic condition in which the body does not produce enough insulin or is unable to use insulin effectively. These drugs work by blocking the reabsorption of glucose in the kidneys, allowing it to be excreted in the urine. This helps to reduce blood glucose levels and improve glycemic control.
The SGLT2 market is highly competitive, with several major pharmaceutical companies offering products. These include AstraZeneca, Boehringer Ingelheim, Eli Lilly, Janssen Pharmaceuticals, Merck, Novo Nordisk, and Sanofi. Each company offers a range of products, including both branded and generic versions. Show Less Read more